Torrent Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹4,979 Cr +50.8% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
TP

Torrent Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹3,303Cr
+17.6% YoY
0% QoQ
Net profit
₹635Cr
+26.2% YoY
+7.4% QoQ
Margin
33%
0 pp YoY
0 pp QoQ
Price₹4,896
Market cap₹1.8L Cr
P/E82.4

The short version

India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.

From Torrent Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. (Page 4)
  • Brazil branded generics market grew 10% YoY; Torrent grew 13% with healthy volume growth and mid-single digit pricing increase; expects 5-6 new product launches in Brazil. (Pages 3, 14)
  • U.S. business saw 12% growth in constant currency; targeting a directional increase in sales with at least 5-7 launches per year and aims to cross $200 million annual sales by FY27. (Pages 3, 9)
  • Germany facing supply disruptions, growth affected; alternative supplier efforts ongoing but will take 3-4 quarters. (Page 4)

2 more points from Torrent Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Torrent Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • There is mention of ongoing work to address supply disruptions in Germany by moving some products to Torrent's own facilities, which implies some capital investment in manufacturing (Page 4).
  • Overall, the focus appears to be on integration with the JB acquisition, operational synergies, and expanding market presence rather than large announced capex at this stage.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Torrent Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Related insights include: - The company has a robust pipeline, for example, 60 molecules awaiting approval at ANVISA (Brazil). - Ongoing active launch plans, including for products like Semaglutide, though some launches may be delayed to the next financial year. - The acquired JB Pharmaceuticals business is being integrated, with expected synergies and growth resuming post-Q4.

2 more points from Torrent Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Torrent Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Torrent Pharmaceuticals Ltd Q3 FY26 results — key figures

Torrent Pharmaceuticals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue3,3032,809+17.6%3,3020%
Operating profit (EBITDA)1,088914+19%1,083+0.5%
Operating margin33%33%0 pp33%0 pp
Profit before tax814691+17.8%791+2.9%
Net profit (PAT)635503+26.2%591+7.4%
EPS (₹)18.7614.86+26.2%17.46+7.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Torrent Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Torrent Pharmaceuticals Ltd Q3 FY26 results?

India business expected to continue outperforming market growth with above-market volume growth; volume growth at ~5.5% for the quarter. Torrent Pharma expects continued healthy double-digit growth in India and Brazil businesses. - India business grew 14% in Q3 FY26 and aims to sustain above-market volume growth supported by new products and price increases. - In Brazil, a 10% constant currency revenue growth was reported with an outlook of 10-15% growth driven by new launches and volume; market growth is 6-7%. - U.S.

What is Torrent Pharmaceuticals Ltd share price analysis?

Torrent Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 82.4 with a market cap of ₹183,832 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Torrent Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.